Inter‐laboratory analytical improvement of succinylacetone and nitisinone quantification from dried blood spot samples
Open Access
- 4 April 2020
- journal article
- research article
- Published by Wiley in JIMD Reports
- Vol. 53 (1), 90-102
- https://doi.org/10.1002/jmd2.12112
Abstract
Background Nitisinone is used to treat hereditary tyrosinemia type 1 (HT‐1) by preventing accumulation of toxic metabolites, including succinylacetone (SA). Accurate quantification of SA during newborn screening is essential, as is quantification of both SA and nitisinone for disease monitoring and optimization of treatment. Analysis of dried blood spots (DBS) rather than plasma samples is a convenient method, but interlaboratory differences and comparability of DBS to serum/plasma may be issues to consider. Methods Eight laboratories with experience in newborn screening and/or monitoring of patients with HT‐1 across Europe participated in this study to assess variability and improve SA and nitisinone concentration measurements from DBS by liquid chromatography‐tandem mass spectrometry (LC‐MS/MS). Quantification of nitisinone from both DBS and plasma was performed to assess sample comparability. In addition, efforts to harmonize laboratory procedures of SA and nitisinone quantifications during 5 rounds of analysis are described. Results Nitisinone levels measured from DBS and plasma strongly correlated (R2 = 0.93). Due to partitioning of nitisinone to the plasma, levels were higher in plasma by a factor of 2.34. In the initial assessment of laboratory performance, all had linear calibrations of SA and nitisinone although there was large inter‐laboratory variability in actual concentration measurements. Subsequent analytical rounds demonstrated markedly improved spread and precision over previous rounds, an outcome confirmed in a final re‐test round. Conclusion The study provides guidance for the determination of nitisinone and SA from DBS and the interpretation of results in the clinic. Inter‐laboratory analytical harmonization was demonstrated through calibration improvements.This publication has 22 references indexed in Scilit:
- Recommendations for the management of tyrosinaemia type 1Orphanet Journal of Rare Diseases, 2013
- LC-MS/MS Method for Simultaneous Determination on a Dried Blood Spot of Multiple Analytes Relevant for Treatment Monitoring in Patients with Tyrosinemia Type IAnalytical Chemistry, 2011
- Tyrosinemia type 1 in Spain: Mutational analysis, treatment and long‐term outcomePediatrics International, 2011
- Newborn screening for Tyr-I: Two years' experience of the New York State programMolecular Genetics and Metabolism, 2011
- Comparison of plasma and dry blood spots as samples for the determination of nitisinone (NTBC) by high-performance liquid chromatography–tandem mass spectrometry. Study of the stability of the samples at different temperaturesJournal of Chromatography B, 2011
- Expanded Newborn Screening: Outcome in Screened and Unscreened Patients at Age 6 YearsPEDIATRICS, 2009
- A GC/MS validated method for the nanomolar range determination of succinylacetone in amniotic fluid and plasma: An analytical tool for tyrosinemia type IJournal of Chromatography B, 2006
- Pharmacokinetics and pharmacodynamics of NTBC (2‐(2‐nitro‐4‐fluoromethylbenzoyl)‐1,3‐cyclohexanedione) and mesotrione, inhibitors of 4‐hydroxyphenyl pyruvate dioxygenase (HPPD) following a single dose to healthy male volunteersBritish Journal of Clinical Pharmacology, 2001
- Screening for tyrosinaemia type I.Archives of Disease in Childhood: Fetal & Neonatal, 1996
- Pitfalls in the initial diagnosis of tyrosinemia: Three case reports and a review of the literatureClinical Biochemistry, 1987